However, it did not reproduce the significance previously found for the lower-dose group, which could partly be explained by a borderline significance in the first trial. 25 An extension to this trial shows ongoing significant reduction of MRI activity favoring the 0.6 mg/day dosage. 26 Two ongoing Phase III trials (ALLEGRO [Assessment of Oral Laquinimod in Preventing Progression of MS] and BRAVO [Benefit–Risk Assessment of Avonex ® and Laquinimod]) will provide further data and hopefully show ongoing favorable safety data.
← all excerpts
Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.
1
—
—